Advanced Search

Submit Manuscript

Volume 32, No 12, Dec 2022

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 32 Issue 12, December 2022: 1036-1037

RESEARCH HIGHLIGHTS

Off-the-shelf CAR T cells to treat cancer

Sofia Castelli , Regina M. Young , Carl H. June*

Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
Correspondence: Carl H. June(cjune@upenn.edu)

Chimeric antigen receptor (CAR) T cell therapies approved for cancer treatment are manufactured from a patient’s own cells (autologous), entailing challenges such as high costs, inconsistent product quality, and potential treatment failure due to T cell dysfunction. In a study published in Cell Research, Hu et al. generated CAR T cells from healthy donor T cells (allogeneic), and these were successful in a clinical trial for the treatment of T cell malignancies.


https://doi.org/10.1038/s41422-022-00745-4

FULL TEXT | PDF

Browse 80